Ekso Bionics (NASDAQ:EKSO) Now Covered by Analysts at Wall Street Zen

Wall Street Zen assumed coverage on shares of Ekso Bionics (NASDAQ:EKSO) in a research note issued to investors on Thursday morning. The brokerage issued a hold rating on the stock.

A number of other equities research analysts have also recently commented on EKSO. HC Wainwright cut their target price on Ekso Bionics from $9.00 to $4.00 and set a “buy” rating on the stock in a research note on Tuesday, May 6th. Lake Street Capital dropped their price objective on Ekso Bionics from $2.00 to $1.00 and set a “buy” rating on the stock in a research report on Tuesday, March 4th.

Ekso Bionics Trading Up 10.4%

NASDAQ EKSO opened at $0.28 on Thursday. Ekso Bionics has a 12 month low of $0.23 and a 12 month high of $1.53. The stock has a market cap of $9.83 million, a P/E ratio of -0.43 and a beta of 1.09. The stock’s fifty day moving average price is $0.42 and its 200-day moving average price is $0.55. The company has a current ratio of 2.81, a quick ratio of 2.14 and a debt-to-equity ratio of 0.28.

Shares of Ekso Bionics are scheduled to reverse split on Tuesday, May 27th. The 1-15 reverse split was announced on Monday, May 19th. The number of shares owned by shareholders will be adjusted after the closing bell on Monday, May 26th.

Ekso Bionics (NASDAQ:EKSO) last released its earnings results on Monday, May 5th. The company reported ($0.12) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.01). Ekso Bionics had a negative return on equity of 83.09% and a negative net margin of 62.95%. The company had revenue of $3.38 million during the quarter, compared to analysts’ expectations of $4.62 million. As a group, equities analysts forecast that Ekso Bionics will post -0.48 EPS for the current fiscal year.

Institutional Investors Weigh In On Ekso Bionics

An institutional investor recently raised its position in Ekso Bionics stock. Armistice Capital LLC lifted its holdings in shares of Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) by 18.4% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,042,382 shares of the company’s stock after buying an additional 316,733 shares during the period. Armistice Capital LLC owned approximately 7.03% of Ekso Bionics worth $823,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 6.42% of the company’s stock.

Ekso Bionics Company Profile

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.